Asia Pacific Cardiac Ablation Market size surpassed USD 740 million in 2021 and is predicted to witness 14.5% CAGR from 2022 to 2028.

Get more details on this report - Request Free Sample PDF

Growing prevalence of cardiovascular diseases is one of the major factors accelerating the Asia Pacific cardiac ablation market growth. For instance, as per the Organisation for Economic Cooperation and Development (OECD), cardiovascular diseases are amongst the leading causes of death in Asia pacific. Therefore, high mortality rate associated with escalating disease burden is anticipated to drive the market demand. Further, government efforts to broaden treatment accessibility catering to the increasing patient population will benefit the industry outlook.

Along with growing patient population, the continuous technological advancements will act as a notable market growth driving factor. Several industry players are involved in the development and commercialization of advanced catheterization devices for the treatment of atrial fibrillation. For instance, in November 2021, Medtronic introduced its Arctic Front Cardiac Cryoablation Catheter in India.

The industry gained momentum with declining number of COVID-19 cases in 2021. Reduced mortality rate and infection severity with availability of treatment and preventive vaccination has enabled regular practice of cardiovascular procedure in healthcare facilities. Thus, the increasing number of patient visits for elective procedures in clinical settings positively impacted the product demand in 2021.

Asia Pacific Market, By Product

Get more details on this report - Request Free Sample PDF

Cryoablation devices segment in the Asia Pacific cardiac ablation market crossed USD 7 million revenue in 2021, attributed to the growing prevalence of cardiac arrhythmia, increased demand for minimally invasive procedures, and rising availability of customized probes for cryoablation.

Additionally, increasing awareness regarding advanced treatment options in rapidly growing economies such as China and India will offer unprecedented growth opportunities to the segment. Moreover, benefits associated with cryoablation procedures including reduced side effects, minimal scarring, easier recovery, and less damage to the surrounding tissues will positively impact the market expansion.

Asia Pacific Market, By Approach

The catheter-based cardiac ablation segment dominated over 70% Asia Pacific cardiac ablation market share in 2021. Increasing awareness regarding benefits associated with catheter-based procedures over surgical treatments among patients will favor the segment growth. Several advantages such as minimal adverse effects, high survival rate and quick relief will influence the procedural volume, thereby ultimately driving the product sales. Additionally, effectiveness and high success rate of catheter-based procedures in the treatment of arrhythmias will propel the segment growth with higher prevalence of cardiac arrhythmia in the region.

Asia Pacific Cardiac Ablation Market, By Application

Atrial fibrillation & flutter segment will reach USD 900 million revenue by 2028, owing to the high incidence rate of atrial fibrillation. Over the years, the incidence rate of atrial fibrillation has consistently increased in the Asia Pacific. Several risk factors such as smoking, obesity and unhealthy lifestyle are significantly contributing to the disease burden of cardiac arrhythmias. Furthermore, rapid population aging in developing countries contribute to the higher incidence of arrhythmic disorders.

Asia Pacific Market, By End-use

Hospitals held more than 60% Asia Pacific cardiac ablation market share in 2021, due to the increasing adoption of cardiac ablation devices. Rising spending ability of hospitals on technologically advanced products along with the presence of skilled expertise will contribute to the market size. Additionally, availability of hospital-based screening and testing equipment offering precise diagnosis and mapping of cardiac disease will drive patient preference for hospital.

Asia Pacific Market, By Country

China cardiac ablation market accounted around 26% revenue share in 2021. Increasing number of patient population suffering from cardiovascular diseases is expected to enhance demand for cardiac ablation devices. According to the data published by the National Library of Medicine in 2019, nearly 5.09 million CVD deaths were reported in China. Thus, growing spending ability on the disease treatment to reduce associated mortalities have boosted the number of cardiac procedures in the country. Furthermore, growing awareness campaigns and government initiatives in order to expand treatment access will benefit the industry expansion.

Competitive Industry Landscape

Prominent industry players include Biosense Webster (Johnson & Johnson), Abbott Laboratories (St. Jude Medical), AngioDynamics, Inc, AtriCure Inc, Biotronik SE & Co. KG, Boston Scientific Corporation, MicroPort Scientific Corporation, Japan Lifeline, Medtronic plc., and Stereotaxis, Inc.

These companies are continuously adopting numerous growth strategies such as product launches, acquisitions & merger, strategic partnerships and collaborations to enhance their performance and cater large patient pool. For instance, in February 2021, Japan Lifeline and  CardioFocus, Inc expanded their existing partnership agreement. The agreement extends timeframe of the distribution agreement for Japan, as well as South Korea and Taiwan of HeartLight X3 System, a catheter ablation technology.